Under the terms of the agreement, the transaction includes an initial payment of $225 million plus potential additional payments contingent upon achievement of certain clinical milestones.
Operating within Medtronic’s cardiac rhythm disease management business, Ablation Frontiers and the recently acquired CryoCath Technologies are believed to expand the company’s recently launched atrial fibrillation solutions business.